Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape & Forecast | G7 | 2024
The multibillion dollar non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL) therapy market is dynamic and experiencing substantial growth. The covalent BTK inhibitors ibrutinib (Imbruvica, J&J Innovative Medicine), acalabrutinib (Calquence, AstraZeneca), and zanubrutinib (Brukinsa, BeiGene) are transforming the treatment of NHL / CLL, and we expect the noncovalent BTK inhibitor pirtobrutinib (Jaypirca, Eli Lilly) to carve out a niche for the treatment of patients who relapse or are refractory to covalent BTK inhibitor therapy. BCL-2 inhibitors, CD20-directed antibodies, and CAR T-cell therapies are also key contributors to NHL / CLL therapy sales. Continued uptake of these agents, and label expansions transitioning their use to earlier lines of treatment will fuel sales over the 2023-2033 forecast period, and contribute to a shift away from conventional immunochemotherapy regimens. BiTEs are the latest class of agent to launch in NHL / CLL, and agents including mosunetuzumab (Lunsumio, Roche), epcoritamab (Epkinly / Tepkinly, Genmab / AbbVie), and glofitamab (Columvi, Roche) will garner substantial uptake and drive market growth over the forecast period.
Questions answered
- What is the size of the clinically and commercially relevant drug-treatable NHL / CLL populations, and how will drug-treatment rates vary by geography, setting, and over time?
- What are the key drivers and constraints of the NHL / CLL therapy market, and how will the market evolve over the 2023-2033 forecast period? Which drug class will dominate the treatment of NHL / CLL?
- What will be the market impact of label expansions of BTK inhibitors, BiTEs, and CAR T-cell therapies into earlier lines of treatment across the different NHL / CLL subtypes?
- What are the most promising emerging therapies in the late-phase pipeline, and how will they shape the NHL / CLL therapy market over the forecast period?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
